Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2004-08-26
2010-12-14
Mondesi, Robert B (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S278100, C424S248100, C424S168100, C424S093460, C530S387100
Reexamination Certificate
active
07850970
ABSTRACT:
A novel method of treating and preventing bacterial diseases is provided. In particular, the present invention relates to compositions and methods for inhibition of Gram negative, Gram positive and acid fast bacilli in general and tuberculosis (TB),mycobacterium aviumcomplex (MAC), and anthrax in particular. Thus, the invention relates to modulation of cellular activities, including macrophage activity, and the like. More particularly, the present invention relates to the inhibitory compounds comprising naturally occurring and man-made inhibitors of serine protease.
REFERENCES:
patent: 4021472 (1977-05-01), Fuji et al.
patent: 4224342 (1980-09-01), Fuji et al.
patent: 4283418 (1981-08-01), Fuji et al.
patent: 4829052 (1989-05-01), Glover et al.
patent: 4829054 (1989-05-01), Emerson et al.
patent: 4857538 (1989-08-01), Kashman et al.
patent: 4963654 (1990-10-01), Katunuma
patent: 5008242 (1991-04-01), Lezdey et al.
patent: 5093316 (1992-03-01), Lezdey et al.
patent: 5134119 (1992-07-01), Lezdey et al.
patent: 5157019 (1992-10-01), Glover et al.
patent: 5175253 (1992-12-01), Fallon et al.
patent: 5216022 (1993-06-01), Oleksyszyn et al.
patent: 5346886 (1994-09-01), Lezdey et al.
patent: 5420110 (1995-05-01), Miller
patent: 5514653 (1996-05-01), Perlmutter
patent: 5604201 (1997-02-01), Thomas et al.
patent: 5610285 (1997-03-01), Lebing et al.
patent: 5612194 (1997-03-01), Rubin et al.
patent: 5616693 (1997-04-01), Hwang et al.
patent: 5710026 (1998-01-01), Sprecher
patent: 5780440 (1998-07-01), Lezdey et al.
patent: 5861380 (1999-01-01), Gyorkos et al.
patent: 5869455 (1999-02-01), Gyorkos et al.
patent: 5874424 (1999-02-01), Batchelor et al.
patent: 5905023 (1999-05-01), Sager et al.
patent: 6022855 (2000-02-01), Thomas et al.
patent: 6124257 (2000-09-01), Lezdey et al.
patent: 6136834 (2000-10-01), Ohmoto et al.
patent: 6174859 (2001-01-01), Lezdey et al.
patent: 6489308 (2002-12-01), Shapiro
patent: 6849605 (2005-02-01), Shapiro
patent: 2004/0220239 (2004-11-01), Shapiro
patent: 2004/0220242 (2004-11-01), Shapiro
patent: 2004/0254349 (2004-12-01), James et al.
patent: 2008/0085854 (2008-04-01), Barr et al.
patent: WO 92/006706 (1992-04-01), None
patent: 93/18794 (1993-09-01), None
patent: 95/28422 (1995-10-01), None
patent: 95/34538 (1995-12-01), None
patent: 97/21690 (1997-06-01), None
patent: 97/33996 (1997-09-01), None
patent: 98/24806 (1998-06-01), None
patent: 00/44390 (2000-08-01), None
patent: 00/51625 (2000-09-01), None
patent: WO 00/051624 (2000-09-01), None
patent: WO 00/51625 (2000-09-01), None
patent: WO 02/012318 (2002-12-01), None
patent: 2005/019434 (2005-03-01), None
patent: 2005/046454 (2005-05-01), None
patent: 2005/112970 (2005-12-01), None
patent: 2007/079312 (2007-07-01), None
eMedicineHealth, Apr. 25, 2007, http://www.emedicinehealth.com/script/main/art.asp?articlekey=59372&pf=3&page=7.
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4).
Dermer (Bio/Technology, 1994, vol. 12 p. 320).
Reenspan et al. (Nature Biotechnology 17: 936-937, 1999).
Anderson, et al., Inhibition of HIV-1 gp160-dependent Membrane Fusion by a Furin-directed a1-Antitrypsin Variant, The Journal of Biological Chemistry, vol. 268, No. 33, pp. 24887-24891, Nov. 25, 1993.
eMedicineHealth, Anthrax, WebMD 2007.
Gaur, et al., “Effect of Nasal immunization with protective antigen of Bacillus anthracis on protective immune response against anthrax toxin,” Vaccine, vol. 20, pp. 2836-2839, 2002.
Leppla, Stephen H., et al., “Development of an improved vaccine for anthrax,” J. Clin. Invest., vol. 109, pp. 141-144, 2002.
Lomas, et al., “Commercial plasma a1-antitrypsin (Prolastin) contains a conformationally inactive, latent component,” Eur Respir J, vol. 10, pp. 672-675, 1997.
Musson, et al., “Differential Processing of CD4 T-cell Epitopes from the Protective Antigen ofBacillus anthracis,” The Journal of Biological Chemistry, vol. 278, No. 52, pp. 52425-52431, 2003.
Shapiro et al., “Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1,” FASEB J 2001, 15(1):115-122.
International Search Report and Written Opinion from International Application PCT No. PCT/US07/061577, mailed Dec. 7, 2007.
International Search Report and Written Opinion from PCT International Application No. PCT/US08/60848, mailed Dec. 22, 2008.
Chan, et al., “Alpha-I-antitrypsin (AAT) anomalies are associated with lung disease due to rapidly growing mycobacteria and AAT inhibits Mycobacterim abscessus infection of macrophages.” Scandinavian Journal of Infectious Diseases 2007, 39(8):690-696.
Lieberman, “Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: A new hypothesis with supporting data.” Chest 2000, 118(5):1480-1485.
Lomas et al., “Preparation and Characterization of Latent alpha-1 antitrypsin,” J Biol Chem 1995, 270:5282-5288.
Simpson et al., “Adenoviral augmentation of elafin protects the lung against acute injury mediated by activated neutrophils and bacterial infection,” J Immunol 2001, 167:1778-1786.
Supplementary European Search Report, EP/04801916, Aug. 17, 2009.
International Search Report and Written Opinion; International Application PCT No. PCT/US04/27711, mailed Jul. 19, 2005.
International Search Report and Written Opinion, International Application PCT No. PCT/US06/22436, mailed Feb. 20, 2007.
Faegre & Benson,LLP
Mondesi Robert B
The Regents of the University of Colorado
Tongue Lakia J
LandOfFree
Inhibitors of serine protease activity and their use in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of serine protease activity and their use in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of serine protease activity and their use in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4227229